Maremmani Angelo G I, Pallucchini Alessandro, Rovai Luca, Bacciardi Silvia, Spera Vincenza, Maiello Marco, Perugi Giulio, Maremmani Icro
Department of Psychiatry, North-Western Tuscany Local Health Unit, Versilian Zone, Viareggio, Italy.
AU-CNS, Association for the Application of Neuroscientific Knowledge to Social Aims, Pietrasanta, Lucca, Italy.
Ann Gen Psychiatry. 2018 Apr 18;17:14. doi: 10.1186/s12991-018-0185-3. eCollection 2018.
Over-standard methadone doses are generally needed in the treatment of heroin use disorder (HUD) patients that display concomitant high-severity psychopathological symptomatology. A flexible dosing regimen may lead to higher retention rates in dual disorder (DD), as we demonstrated in bipolar 1 HUD patients, leading to outcomes that are as satisfactory as those of HUD patients without high-severity psychopathological symptomatology.
This study aimed to compare the long-term outcomes of treatment-resistant chronic psychosis HUD patients (PSY-HUD) with those of peers without dual disorder (HUD).
85 HUD patients who also met the criteria for treatment resistance-25 of them affected by chronic psychosis and 60 without DD-were monitored prospectively for up to 8 years while continuing to receive enhanced methadone maintenance treatment.
The rates of endurance in the treatment of PSY-HUD patients were 36%, compared with 34% for HUD patients ( = 0.872). After 3 years of treatment, these rates tended to become progressively more stable. PSY-HUD patients showed better outcome results than HUD patients regarding CGI severity ( < 0.001) and DSM-IV-GAF ( < 0.001). No differences were found regarding good toxicological outcomes or the methadone dosages used to achieve stabilization. The time required to stabilize PSY-HUD patients was shorter ( = 0.034).
An enhanced methadone maintenance treatment seems to be equally effective in patients with PSY-HUD and those with HUD.
在治疗伴有高严重度精神病理症状的海洛因使用障碍(HUD)患者时,通常需要超标准剂量的美沙酮。灵活的给药方案可能会提高双相障碍(DD)患者的留存率,正如我们在双相I型HUD患者中所证明的那样,从而产生与没有高严重度精神病理症状的HUD患者同样令人满意的结果。
本研究旨在比较难治性慢性精神病性HUD患者(PSY-HUD)与无双相障碍的同龄人(HUD)的长期治疗结果。
85名同时符合难治性标准的HUD患者——其中25名患有慢性精神病,60名无双相障碍——在继续接受强化美沙酮维持治疗的同时,进行了长达8年的前瞻性监测。
PSY-HUD患者的治疗耐受率为36%,而HUD患者为34%( = 0.872)。治疗3年后,这些比率趋于逐渐稳定。在CGI严重程度( < 0.001)和DSM-IV-GAF( < 0.001)方面,PSY-HUD患者的治疗结果优于HUD患者。在良好的毒理学结果或用于实现稳定的美沙酮剂量方面未发现差异。使PSY-HUD患者达到稳定所需的时间更短( = 0.034)。
强化美沙酮维持治疗似乎对PSY-HUD患者和HUD患者同样有效。